For research use only. Not for therapeutic Use.
Halofantrine Hydrochloride（Cat No.:R046742）is an antimalarial medication used to treat Plasmodium falciparum and Plasmodium vivax infections. It belongs to the phenanthrene methanol class and works by disrupting the parasite’s membrane function, likely through interaction with heme, a toxic byproduct of hemoglobin digestion. Halofantrine Hydrochloride is effective against multidrug-resistant malaria strains, making it valuable in regions with limited treatment options. Administered orally, it has a rapid onset of action but requires careful dosing due to potential cardiotoxicity. Its role in malaria therapy supports global efforts to combat this life-threatening disease.
| Catalog Number | R046742 |
| CAS Number | 36167-63-2 |
| Synonyms | 1,3-Dichloro-α-[2-(dibutylamino)ethyl]-6-(trifluoromethyl)-9-phenanthrenemethanol;?(+/-)-Halofantrine Hydrochloride; Halfan Hydrochloride; SKF 102886; WR 171669; |
| Molecular Formula | C26H31Cl3F3NO |
| Purity | ≥95% |
| Storage | -20°C |
| IUPAC Name | 3-(dibutylamino)-1-[1,3-dichloro-6-(trifluoromethyl)phenanthren-9-yl]propan-1-ol;hydrochloride |
| InChI | InChI=1S/C26H30Cl2F3NO.ClH/c1-3-5-10-32(11-6-4-2)12-9-25(33)23-16-22-21(14-18(27)15-24(22)28)20-13-17(26(29,30)31)7-8-19(20)23;/h7-8,13-16,25,33H,3-6,9-12H2,1-2H3;1H |
| InChIKey | WANGFTDWOFGECH-UHFFFAOYSA-N |
| SMILES | CCCCN(CCCC)CCC(C1=C2C=CC(=CC2=C3C=C(C=C(C3=C1)Cl)Cl)C(F)(F)F)O.Cl |
| Reference | </br>1:Partitioning of halofantrine hydrochloride between water, micellar solutions, and soybean oil: Effects on its apparent ionization constant. Taillardat-Bertschinger A, Perry CS, Galland A, Prankerd RJ, Charman WN.J Pharm Sci. 2003 Nov;92(11):2217-28. PMID: 14603507 </br>2:Effects of halofantrine hydrochloride (halfan) on the histology of the ovary of mature female Wistar rats. Adjene JO, Agoreyo FO.Afr J Reprod Health. 2003 Apr;7(1):113-20. PMID: 12816318 </br>3:A physicochemical basis for the extensive intestinal lymphatic transport of a poorly lipid soluble antimalarial, halofantrine hydrochloride, after postprandial administration to dogs. Khoo SM, Prankerd RJ, Edwards GA, Porter CJ, Charman WN.J Pharm Sci. 2002 Mar;91(3):647-59. PMID: 11920750 </br>4:X-ray crystal structure of the antimalarial agent (-)-halofantrine hydrochloride supports stereospecificity for cardiotoxicity. Karle JM.Antimicrob Agents Chemother. 1997 Apr;41(4):791-4. PMID: 9087491 Free PMC Article</br>5:In vivo sensitivity of Plasmodium falciparum to halofantrine hydrochloride in Burkina Faso. Del Nero L, Lamizana L, Nebie I, Sare S, Bougouma L, Pietra V.Am J Trop Med Hyg. 1994 Jan;50(1):102-6. PMID: 8304564 </br>6:A new micronized formulation of halofantrine hydrochloride in the treatment of acute Plasmodium falciparum malaria. Gillespie SH, Msaki EP, Ramsay A, Ngowi FI, Fox R.Trans R Soc Trop Med Hyg. 1993 Jul-Aug;87(4):467-9. PMID: 8249083 </br>7:Halofantrine hydrochloride–efficacy and safety in children with acute malaria. Khan MA, Rehman GN, Qazi SA.J Pak Med Assoc. 1991 Jan;41(1):8-10. PMID: 1900550 Free Article</br>8:[Halofantrine hydrochloride in the treatment of Plasmodium falciparum malaria in a region of resistance. Analysis of 54 pediatric cases]. Mashako MN, Kingway MP, Kayembe N.Ann Soc Belg Med Trop. 1990 Mar;70(1):25-32. French. PMID: 2196007 </br>9:Structure of the antimalarial halofantrine hydrochloride. Karle JM, Karle IL.Acta Crystallogr C. 1989 Aug 15;45 ( Pt 8):1248-50. PMID: 2604946 </br>10:Clinical trials with halofantrine hydrochloride in Malawi. Wirima J, Khoromana C, Molyneux ME, Gilles HM.Lancet. 1988 Jul 30;2(8605):250-2. PMID: 2899238 |
